Thomas McGonigal

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index2.0kcitations33works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA Repair Mechanisms(7), Cell Adhesion Molecules Research(5), PI3K/AKT/mTOR signaling in cancer(5), PARP inhibition in cancer therapy(5), HER2/EGFR in Cancer Research(4)

Publications33 total

Supplementary Data from Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
2023Open Access
Supplementary Data from Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
2023Open Access
Data from Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
2023Open Access
Data from Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
2023Open Access
Supplementary Figure Legends from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Table S1 from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Table S1 from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Supplementary Figure Legends from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Supplementary Figures S1-S7 from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Data from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Data from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
Supplementary Figures S1-S7 from LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
2023Open Access
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates
Cancer Research·2018· 189 cited
The Volume of Three-Dimensional Cultures of Cancer Cells In Vitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors
Neoplasia·2017· 35 citedOpen Access
ABBV-085 is a novel antibody–drug conjugate (ADC) that targets LRRC15 in the tumor microenvironment
European Journal of Cancer·2016· 2 cited
Clearance of systemic hematologic tumors by venetoclax (Abt‐199) and navitoclax
Pharmacology Research & Perspectives·2015· 26 citedOpen Access
Abstract C249: Detection of tissue and bone marrow clearance of systemically engrafted hematologic tumors by ABT-199 and navitoclax using bioluminescent imaging.
Molecular Cancer Therapeutics·2013
Abstract A161: Acquired resistance to combination treatment with TMZ and ABT-888 is mediated by both BER and HR DNA repair pathways
Molecular Cancer Therapeutics·2009
Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
Molecular Cancer Research·2009· 91 cited
Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is an Akt substrate both in vitro and in cells.
PubMed·2008· 50 cited
page 1 of 2Next →

Frequent Co-authors

Joann P. Palma(16), Edward K. Han(13), Vincent L. Giranda(13), Jonathan A. Hickson(13), Saul H. Rosenberg(11), Tamar Uziel(11), Xuesong Liu(10), Joel Johansson(10), Sonia G. Tanlimco(10), Melvin Fox(10), Mien Sho(10), Rick Powers(10), Josue Samayoa(10), Diane Hollenbaugh(10), Kurt Gish(10), Susan E. Morgan-Lappe(10), Eric D. Hsi(10), James W. Purcell(9), Lisa Durkin(9), Subashri Kumar(9)